1. House MG, Ito H, Gönen M et al (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1600 patients during two decades at a single institution. J Am Coll Surg 210:744–752
2. Kopetz S, Chang GJ, Overman MJ et al (2009) Improved sur- vival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683
3. Khatri VP, Petrelli NJ, Belghiti J (2005) Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 23:8490–8499
4. Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long- term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766
5. Khoo E, O’Neill S, Brown E et al (2016) Systematic review of sys- temic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford) 18:485–493
6. Nigri G, Petrucciani N, Ferla F et al (2015) Neoadjuvant chem- otherapy for resectable colorectal liver metastases: what is the evidence? results of a systematic review of comparative studies. Surgeon 13:83–90
7. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016
8. Nordlinger B, Sorbye H, Glimelius B et al (2013) Periopera- tive FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215
9. Hokuto D, Nomi T, Yasuda S et al (2018) Risk factors for unre- sectable recurrence after up-front surgery for colorectal liver metastasis. World J Surg 42:884–891
10. Ayez N, van der Stok EP, Grünhagen DJ et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur J Surg Oncol 41:859–867
11. Tanaka K, Adam R, Shimada H et al (2003) Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. BJS 90:963–969
12. Beppu T, Sakamoto Y, Hasegawa K et al (2012) A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collec- tion as a project study for hepatic surgery of the Japanese society of hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci 19:72–84
13. Konopke R, Kersting S, Distler M et al (2009) Prognostic fac- tors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 29:89–102
14. Rees M, Tekkis PP, Welsh FK et al (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247:125–135
15. Nagashima I, Takada T, Adachi M et al (2006) Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive num- ber of risk factors. World J Gastroenterol 12:6305–6309
16. Iwatsuki S, Dvorchik I, Madariaga JR et al (1999) Hepatic resec- tion for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189:291–299
17. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for pre- dicting recurrence after hepatic resection for metastatic colo- rectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318
18. Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resec- tion of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer 77:1254–1262
19. Zakaria S, Donohue JH, Que FG et al (2007) Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 246:183–191
20. Sasaki K, Morioka D, Conci S et al (2018) The tumor burden score: a new, “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 267:132–141
21. Ayez N, van der Stok EP, de Wilt H et al (2015) Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high- risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer 15:180
22. Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with sur- gery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982
23. Kato T, Uehara K, Maeda A et al (2015) Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial. Cancer Chemother Pharmacol 75:1281–1288
24. Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemo- therapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:4906–4911
25. Mukai T, Uehara K, Goto H et al (2017) Phase II trial of neoad- juvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial). Jpn J Clin Oncol 47:597–603
26. Margonis GA, Sasaki K, Gholami S et al (2018) Genetic and mor- phological evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg 105:1210–1220
27. Primrose J, Falk S, Finch-Jones M et al (2014) Systemic chemo- therapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:601–611
論文の公開元へ
